We are a digital health company revolutionizing dermatology by introducing standardization and objectivity in the process of skin imaging and assessment by our mobile medical device system Scarletred®Vision
Our product, Scarletred®Vision is designed to make diagnostic assessment in dermatology objective. Our product is easy to use and allows you to develop better skin care products and health care services faster at a significant lower cost.
Certified and secure technology. Patented worldwide
Applications
Scarletred®Vision can be used in any of the more than 3.000 skin diseases, primarily, at present, in drug trials, cosmetics studies and medical routine in …
Our clients
Our award winning technology is supplied internationally to biopharma, cosmetics companies, hospitals, insurance companies, CRO's and medical experts.
Biopharma
Cosmetic
Hospitals
Experts
Immediate benefits
Saving costs
Working with Scarletred®Vision is very cost efficient. Automation of time and error prone process steps lead to 90% cost reduction.
Real-time
We enable remote monitoring and analysis which leads to two times higher patient compliance.
Objective data
Standardization of skin imaging and scoring with Scarletred®Vision leads to superior data quality.
Certified
Scarletred®Vision is CE class I registered mobile medical device.
Scope
Scarletred®Vision can be used in a broad range of dermatological applications.
User-friendly
Our products are very easy to use.
Hardware independent
Subscription ensures that your tools are up to date and reduces your infrastructure cost.
Automation
QR and trial codes increase data safety and automate data allocation.
Mobile
The system is 100% mobile.
Epidermolysis bullosa - How does remote wound care in rare skin diseases work?
Children living with epidermolysis bullosa (EB) are often called "butterfly children", comparing the fragility of skin with that of butterfly wings. It is a very severe, rare disease affecting approx. 1 of 25000 people worldwide. EB is manifested by extremely fragile, blistering skin with a compromised wound healing process.
Hidradenitis suppurativa - Pharma goes digital to accelerate clinical drug development
Hidradenitis suppurativa (HS) is an autoinflammatory skin condition affecting about 1% of the total population. Due to the characteristics of its symptoms, HS patients experience embarrassment and reluctance to visit the practitioner, therefore, treatment often starts when the disease is already far progressed.
Houskapreis 2020: SCARLETRED is nominated for Austria's largest private research award
The research award has been awarded annually by the B&C Private Foundation. With the Houska Prize, the B&C private foundation is committed to improving research conditions and cutting-edge research in Austria.
Chronic wounds - Objective telemedicine and remote wound care 2.0 made in Austria
Chronic wound is a serious medical condition, affecting up to 4 % of all people worldwide. It significantly decreases the QOL of patients, in hand with other financial and social burden and comorbidities. The wound care market is one of the biggest in the healthcare system globally, standing now at approx. USD 10.4 billion, therefore, the availability of up-to-date and inn...
Let's get started
Our flexible SaaS model enables easy up-, and down-scaling according to your demands.
Find out more via one of these four steps.
